BioBDx Funding: How Much Did They Raise & Key Investors

How Much Did BioBDx Raise?
Funding & Key Investors

BioBDx has solidified its position within the behavioral health sector, securing a total capital infusion of $22.3M. This trajectory of financial backing, punctuated by a recent strategic investment of $3.1M, underscores the market confidence in the company's proprietary diagnostic systems. By focusing on quantitative assessment tools, BioBDx is addressing critical gaps in the clinical evaluation of behavioral disorders, moving beyond subjective observation toward data-driven diagnostic precision.

The company's funding history reflects a disciplined approach to growth, beginning with early-stage support and evolving into significant debt and equity financing rounds. This capital structure has enabled the firm to transition from initial research and development to the commercialization of its flagship diagnostic platforms, positioning it as a pivotal player in the intersection of medical technology and mental health diagnostics.

What is BioBDx?

BioBDx

Manufacturing

Medical Devices & Equipment

Healthcare Services

BioBehavioral Diagnostics Company, known as BioBDx, is a specialized medical technology firm dedicated to the development, manufacturing, and marketing of objective diagnostic systems for behavioral disorders. Its core innovation, the McLean Motion and Attention Test (MMAT/ADHD System), provides clinicians with a standardized, quantitative framework for diagnosing ADHD. By facilitating office-based assessments, the company aims to streamline the diagnostic process, ensuring that patients receive prompt and evidence-based treatment plans. This focus on objective metrics represents a significant shift in the standard of care for neurodevelopmental conditions.

How much funding has BioBDx raised?

BioBDx has raised a total of $22.3M across 4 funding rounds:

2007

Series A

$8.5M

2010

Series B

$10M

2011

Debt

$700K

Debt

$3.1M

Series A (2007): $8.5M with participation from Sevin Rosen Funds' companies and Tullis-Dickerson & Co.

Series B (2010): $10M led by Sevin Rosen Funds and Tullis Health Investors

Debt (2011): $700K, investors not publicly disclosed

Debt (2011): $3.1M, investors not publicly disclosed

Key Investors in BioBDx

Sevin Rosen Funds

Sevin Rosen Funds is a veteran venture capital firm with a historical focus on pioneering technology and high-growth sectors, providing essential early-stage support to innovative enterprises.

Tullis Health Investors

Tullis Health Investors is a private equity firm specializing in commercial-stage healthcare companies, focusing on medical devices and biotechnology to drive long-term value in global health.

Tullis-Dickerson & Co.

Tullis-Dickerson & Co. is an investment entity focused on supporting scalable healthcare solutions and medical technology advancements.

What's next for BioBDx?

With the recent infusion of capital, BioBDx is well-positioned to scale its commercial operations and expand the clinical adoption of its diagnostic systems. The strategic focus will likely center on broadening the application of its proprietary technology to encompass a wider range of behavioral health conditions, thereby increasing its total addressable market. As the healthcare industry continues to prioritize objective, data-backed diagnostic tools, BioBDx is poised to leverage its existing infrastructure to enhance clinical outcomes and solidify its market leadership in the behavioral health technology space.

See full BioBDx company page

See More Financial Insights